Evommune (EVMN) Shares Outstanding (Diluted Average) (2024 - 2026)
Evommune (EVMN) reported Shares Outstanding (Diluted Average) of $33.7 million for Q1 2026, up 2093.54% year-over-year from $1.5 million in Q1 2025, and up 448.67% on a QoQ basis from $6.1 million in Q4 2025.
Evommune (EVMN) has 3 years of Shares Outstanding (Diluted Average) data on file, last reported at $33.7 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) rose 2093.54% year-over-year to $33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.7 million (up 2093.54% YoY) and the FY2025 annual result came in at $6.1 million, up 306.86% from the prior year.
- Shares Outstanding (Diluted Average) grew to $33.7 million in Q1 2026 per EVMN's latest filing, from $6.1 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $33.7 million in Q1 2026 and bottomed at $1.5 million in Q4 2024.
- The 3-year median for Shares Outstanding (Diluted Average) is $1.5 million (2025), against an average of $7.7 million.
- The widest annual swing landed in 2025, when Shares Outstanding (Diluted Average) rose 1.59%; it then soared 2093.54% in 2026.
- Tracing EVMN's Shares Outstanding (Diluted Average) over 3 years: stood at $1.5 million in 2024, then surged by 306.86% to $6.1 million in 2025, then surged by 448.67% to $33.7 million in 2026.
- Per Business Quant, the three latest EVMN Shares Outstanding (Diluted Average) figures stand at $33.7 million (Q1 2026), $6.1 million (Q4 2025), and $1.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | 33.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.67 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.52 Mn |